International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Call for Papers | Fully Refereed | Open Access | Double Blind Peer Reviewed

ISSN: 2319-7064




Downloads: 0 | Views: 160

Research Paper | Pathology | India | Volume 11 Issue 12, December 2022 | Rating: 4.7 / 10


Role of FNAC in the Diagnosis of Salivary Gland Lesions

Dr. Naima Aziz | Dr Roop Rekha Das | Dr Mayuri Saikia


Abstract: Background: Salivary gland tumours account for 1% to 5% of all head and neck tumours. Fine needle aspiration cytology (FNAC) is used as an initial diagnostic tool for salivary gland swelling. The aim of this study is to evaluate cytological spectrum of salivary gland lesions and its correlation with age, gender and anatomical site. We have done a retrospective study of FNAC for salivary gland lesions for a period of 1 year (2020 - 2021) in a tertiary care center of Northeast India. Results: Out of 47 cases of salivary gland lesions, we have found 51.1% non - neoplastic lesions, 31.2% benign lesions and 17% malignant tumours. The majority of the salivary gland lesions were seen in the age group of 51 to 60 years. The male to female ratio of salivary gland lesions was 1.4: 1 and parotid gland (68.08%) was found to be the most commonly involved site. Pleomorphic adenoma was the most common benign tumour (52.2%) and mucoepidermoid carcinoma was the most common malignant tumour (17.4%) among all the neoplasms. Conclusion: Fine needle aspiration cytology is a rapid, cost - effective, and safe diagnostic procedure useful in the initial preoperative diagnosis of salivary gland lesions to plan for appropriate treatment. However, it should be correlated with histopathological confirmation.


Keywords: FNAC, mucoepidermoid carcinoma, pleomorphic adenoma, retrospective study, salivary gland


Edition: Volume 11 Issue 12, December 2022,


Pages: 936 - 939


How to Download this Article?

Type Your Valid Email Address below to Receive the Article PDF Link


Verification Code will appear in 2 Seconds ... Wait

Top